Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 2/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 16/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 16/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577582 | 0.96 | VDR (0.48) | VDRNR1H2NR1H3NR1I2MLYCD | |
| SCHEMBL4891361 | 0.94 | VDR (0.53) | VDRNR1H2NR1H3NR1I2MLYCD | |
| SCHEMBL4893090 | 0.92 | VDR (0.58) | VDRNR1H2NR1H3NR1I2 | |
| SCHEMBL4884687 | 0.91 | VDR (0.52) | VDRNR1H2NR1H3MLYCDPGR | |
| SCHEMBL4895050 | 0.90 | VDR (0.65) | VDRNR1H2NR1H3NR1I2 | |
| SCHEMBL6579160 | 0.89 | VDR (0.60) | VDRNR1H2NR1H3NR1I2MLYCD | |
| SCHEMBL4886580 | 0.87 | VDR (0.63) | VDRNR1H2NR1H3PGR | |
| SCHEMBL4883569 | 0.85 | VDR (0.60) | VDRNR1H2NR1H3NR1I2 | |
| SCHEMBL6579866 | 0.85 | VDR (0.68) | VDRNR1H2NR1H3NR1I2MLYCD | |
| SCHEMBL4891131 | 0.84 | VDR (0.65) | VDRNR1H2NR1H3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | GALDERMA RESEARCH AND DEVELOPMENT (FR) | 2008-08-14 | — | — | US | claimed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | claimed |
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | GALDERMA RESEARCH AND DEVELOPMENT (FR) | 2008-08-14 | — | — | US | disclosed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195259-A1 | Triaromatic vitamin D analogues | CYP24A1, CYP2R1, VDR | VDR 3/4885NR1H2 157/4885NR1H3 158/4885 |
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | CYP24A1, VDR, SOST | VDR 2/4885NR1H2 278/4885NR1H3 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.